Early stage TEN. Photo by Jay2Base via Wikimedia Commons Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) may be rare, but for many patients the crisis does not end at hospital discharge. A new qualitative study published in JAMA Dermatology  describes years of persistent physical, psychological, and social fallout—and a striking absence of structured post-discharge care. Investigators at Vanderbilt University Medical Center’s Center for Drug Safety and Imm

The FPR1-inhibitory activity of the candidate compounds was evaluated using an in vitro SJS/TEN assay. Cell death inhibition was assessed by live/dead staining following treatment with various concentrations of each compound. Among the seven candidates, CDCA exhibited a specific and potent inhibitory effect on cell death, even at low concentrations. Image modified from Kimura H et al., Nat Commun . 2025. A Japanese research group has identified a promising therapeutic candida

Dr. Neil Shear is launching a new podcast, Shear Listening Pleasure (SLP). In this program, the former Head of Dermatology at Sunnybrook Health Sciences Centre in Toronto and professor emeritus at the University of Toronto speaks with patients, physicians and researchers from the world of dermatology. In the first episode, Dr. Shear speaks with Sonia Whyte-Croasdaile, founder of SJS Canada , about her patient journey with Stevens-Johnson Syndrome, the importance of patient su